The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: A placebo controlled study

Gynecological Endocrinology

Volumn 13, Issue 1, 1999, Pages 48-55

  Leather, A T ^a   Studd, J W W ^a   Watson, N R ^a   Holland, E F N ^a  

^a LISTER HOSPITAL   (United Kingdom)

Author keywords

'Add back' estrogen; Goserelin; Premenstrual syndrome

Indexed keywords

ESTRADIOL VALERATE; GOSERELIN; NORETHISTERONE;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; FEMALE; FLUSHING; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

EID: 0032991826     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513599909167531     Document Type: Article

References (32)

1. 1. O'Brien PMS. Helping women with premenstrual syndrome. Br Med J 1993;307:1471-5
2. 2. Frank RT. The hormonal basis of premenstrual tension. Arch Neurol Psychiatry 1931;26:1053-7
3. 3. Stickler RC. Endocrine hypothesis for the etiology of premenstrual syndrome. Clin Obstet Gynecol 1987;30:377-85
4. 4. Studd JWW. Premenstrual tension syndrome. Br Med J 1979;i:410
5. 5. Backstrom T, Boyle H, Baird DT. Persistence of symptoms of premenstrual tension in hysterectomised women. Br J Obstet Gynaecol 1981;88: 530-6
6. 6. Leather AT, Holland EFN, Andrews GN, et al. A study of the referral patterns and therapeutic experiences of a hundred women attending a specialist premenstrual syndrome clinic. J R Soc Med 1993; 86:199-201
7. 7. Magos AL, Brincat M, Studd JWW. Treatment of the premenstrual syndrome by subcutaneous oestradiol implants and cyclical norethisterone: placebo controlled study. Br Med J 1986;292:1629-33
8. 8. Watts JF, Butt RW, Logan Edwards R. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987;94:30-4
9. 9. Deeny M, Hawthorn R, McKay Hart D. Low dose danazol treatment of the premenstrual syndrome. Postgrad Med J 1991;61:450-4
10. 10. Watson NR, Studd JWW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989;ii:730-2
11. 11. Muse KN, Cetal NS, Futterman LA, et al. The premenstrual syndrome effects of 'medical ovariectomy'. N Engl J Med 1984;311:1345-9
12. 12. Hammarback S, Backstrom T. Induced anovulation as a treatment of premenstrual tension syndrome - a double blind crossover study with LRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988;67:159-63
13. 13. Hussain SY, Massil JH, Matta WH, et al. Buserlin in premenstrual syndrome. Gynecol Endocrinol 1992;6: 57-64
14. 14. Studd JWW, Thom M. Oestrogen and endometrial cancer. In: Studd J, ed. Progress in Obstetrics and Gynecology. Vol. 1. London: Churchill Livingstone, 1981:182-98
15. 15. Magos AL, Brewster E, Singh R, et al. The effect of norethisterone in post-menopausal women on oestrogen replacement therapy; a model for premenstrual syndrome. Br J Obstet Gynaecol 1986;93: 1290-9
16. 16. Ganger KF, Fraser D, Whitehead MI, et al. Prolonged endometrial stimulation with oestradiol implants. Br Med J 1990;300:436-8
17. 17. Watson NR, Studd JWW, Savvas M, et al. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol 1990;4:99-107
18. 18. Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotrophin-releasing hormone agonist and danazol. Fertil Steril 1989;52: 21-6
19. 19. Dodin S, Lemay A, Maheux R, et al. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 1991; 7:410-15
20. 20. Leather AT, Studd JWW, Watson NR, et al. The prevention of bone loss in young women treated with GnRH analogs with 'add-back' estragon therapy. Obstet Gynecol 1993;81:104-7
21. 21. Comite F. GnRH analogs and safety. Obstet Gynecol Surv 1989;44:319-25
22. 22. Friedman AJ. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil Steril 1989;51:526-8
23. 23. Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991;98:1155-9
24. 24. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotrophin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991;71:252A-252F
25. 25. Moos RH. The development of a menstrual distress questionnaire. Psychosom Med 1968;30: 853-67
26. 26. Magos AL, Studd JWW. Assessment of menstrual cycle symptoms by trend analysis. Am J Obstet Gynecol 1986;155:271-7
27. 27. Shaw RW, Fraser HM, Boyle H. Intranasal treatment with luteinizing hormone releasing hormone agonist in women with endometriosis. Br Med J 1983;287:1667-9
28. 28. Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. Br J Obstet Gynaecol 1984;91:913-16
29. 29. West CP, Lumsden MA, Lawson S, et al. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987;48:45-51
30. 30. Riis BJ, Christiansen C, Johansen JS, et al. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990;70:920-4
31. 31. Abdalla H, Hart DM, Lindsay R, et al. The prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985;66: 789-92
32. 32. Leather AT, Studd JWW. Estrogen replacement therapy without the withdrawal bleed. In: Asch R, Studd J, eds. Annual Progress in Reproductive Medicine. Carnforth, UK: Parthenon Publishing, 1993:291-300